<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01734278</url>
  </required_header>
  <id_info>
    <org_study_id>OBSERVA</org_study_id>
    <nct_id>NCT01734278</nct_id>
  </id_info>
  <brief_title>Observational Post-Authorisation Safety Study of Asenapine (Sycrest)</brief_title>
  <acronym>OBSERVA</acronym>
  <official_title>An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Saad Shakir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drug Safety Research Unit, Southampton, UK</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the use and short term safety of
      Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United
      Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by
      the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the
      manufacturer of Sycrest.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of selected identified risks of asenapine in the mental health care trust setting</measure>
    <time_frame>12 weeks after asenapine is first prescribed</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Manic Disorder</condition>
  <arm_group>
    <arm_group_label>Asenapine</arm_group_label>
    <description>Patients prescribed asenapine for any indication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>Asenapine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients prescribed asenapine in a NHS Mental Health Trust in England.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for whom a study questionnaire containing useful information has been
             returned

        Exclusion Criteria:

          -  Patients who do not provide consent

          -  Patients within selected institutions (for example prisons)

          -  Patients who commenced treatment between date of market launch (to be confirmed) and
             study start

          -  Enrolled patients for whom both the baseline and 12-week questionnaires are returned
             blank (contain no clinical information)

          -  Enrolled patients for whom the psychiatrist, designated member of clinical care team,
             or study facilitator from the DSRU reports that the patient did not take or was never
             prescribed asenapine

          -  Enrolled patients for whom there is evidence to suggest duplication of patients

          -  Enrolled patients for whom informed written or verbal notification is received by DSRU
             indicating that they no longer wish to participate at any stage of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Staffordshire and Shropshire Healthcare NHS Foundation Trust</name>
      <address>
        <city>Stafford</city>
        <state>Staffordshire</state>
        <zip>ST16 3SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2012</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Drug Safety Research Unit, Southampton, UK</investigator_affiliation>
    <investigator_full_name>Professor Saad Shakir</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

